Denali Therapeutics (NASDAQ:DNLI) Given New $26.00 Price Target at Wedbush
Denali Therapeutics (NASDAQ:DNLI – Free Report) had its target price cut by Wedbush from $30.00 to $26.00 in a research report released on Friday morning, Benzinga reports. They currently have an outperform rating on the stock. Several other research firms have also recently weighed in on DNLI. Stifel Nicolaus lowered their target price on Denali […]
More Stories
Elementis (OTCMKTS:ELMTY) Hits New 52-Week High – Here’s What Happened
Elementis plc (OTCMKTS:ELMTY – Get Free Report) shares reached a new 52-week high on Monday . The stock traded as...
iShares Short Duration Bond Active ETF (BATS:NEAR) Hits New 1-Year High – What’s Next?
iShares Short Duration Bond Active ETF (BATS:NEAR – Get Free Report) hit a new 52-week high on Monday . The...
Nuveen ESG Large-Cap Growth ETF (BATS:NULG) Reaches New 1-Year High – Should You Buy?
Nuveen ESG Large-Cap Growth ETF (BATS:NULG – Get Free Report) reached a new 52-week high during trading on Monday ....
Scout24 (ETR:G24) Sets New 52-Week High – Here’s Why
Scout24 SE (ETR:G24 – Get Free Report) shares hit a new 52-week high during trading on Monday . The company...
iShares MSCI USA Value Factor ETF (BATS:VLUE) Hits New 12-Month High – Time to Buy?
iShares MSCI USA Value Factor ETF (BATS:VLUE – Get Free Report)’s share price hit a new 52-week high during mid-day...
iShares MSCI Chile ETF (BATS:ECH) Reaches New 12-Month Low – Time to Sell?
iShares MSCI Chile ETF (BATS:ECH – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on...